Slide 1: The Future is Synthetic
The Future is Synthetic 4basebio Investor Update 30 June 2025 1
Slide 2: Disclaimer
Disclaimer This document is intended for shareholders, prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estim
Slide 3: Today's Presenters
Today’s Presenters Dr. Heikki Lanckriet, PhD. David Roth CEO / CSO CFO • Chartered accountant with a background in professional services, private equity and listed • 20+ years commercial and scientific experience in life companies, where he has held senior positions over the past 20 years sciences •
Slide 4: Business & Market Overview
Business & Market Overview i} Abasebio
Slide 5: Company Overview
Company Overview 23,000 120+ sq.ft. of Facilities FTEs Cambridge, UK 7 5 GMP-Licensed Proprietary Enzyme Clean Rooms DNA Designs Manufacturing 90+ 10 +35% Customers FTEs in Commercial Customer growth 5
Slide 6: Recent Achievements
Recent Achievements MHRA GMP license Mar ‘25 Commercial team expansion DNA revenue doubled Jan ‘25 Dec ‘24 Entered Clinic Capital Raise Mar ‘24 July ‘24 Delivering on Milestones - Poised for Growth and Success 6 6
Slide 7: MHRA Certification
MHRA Certification “The GMP certification (MIA) granted by the MHRA authorises 4basebio to manufacture and supply both Investigational Medicinal Product (IMP) Drug Substance (Active Pharmaceutical Ingredient; API) and Critical Starting Biological Medicinal materials used in Advanced Therapy Medicina
Slide 8: State of the Nation: Tail winds, Head winds
State of the Nation Tail winds Opportunity Drivers Market Drivers ● T1 pharma opportunities ● Biotech investment climate remains suppressed; ● CDMO partnerships funding of client projects delayed or at risk ● APAC expansion Political Drivers ● Expanded commercial team Credibility Drivers ● Geo-polit
Slide 9: 4bb synthetic DNA platform
Technology Platform with Game-Changing Synthetic DNA Products Application End-Market Opportunity(1) 4bbDNA Products DNA Structure Description ~$30bn • Partially opened, linear, double stranded DNA IVT mRNA opDNATM product • Each molecule features a hairpin on either the 3’ or 5’ end, with an opposit
Slide 10: 4basebio's Platform Delivers Cost-Effective-to-Scale DNA
4basebio’s Platform Delivers Cost-Effective-to-Scale DNA DNA competitive landscape Leader in Synthetic DNA Incumbent DNA Other Plasmid PCR RCA-based source for C> RCA platforms are key and vaccines Amplification based platform competitor to plasmid DNA Cost- Effectiveness ● ◑ ◔ ◑ RCA PCR Other Pla
Slide 11: 4bb Synthetic DNA – Positioning Against Plasmid DNA
4bb Synthetic DNA – Positioning Against Plasmid DNA ✓ Cost-Effectiveness ✓ Flexibility of Scale ✓ Utility of Application / Complexity 10g opDNATM oeDNATM 50mg hpDNATM plasmid 4bb DNA Production at any scale osDNATM • Low labour and capital demands • 4basebio’s platform flexibility allows for the gen
Slide 12: 4bb Synthetic DNA – Positioning Against Synthetic DNA players
4bb Synthetic DNA – Positioning Against Synthetic DNA players ✓ No plasmid amplification ✓ ✓ Higher Higher purity purity DNA DNA Selectable Promoter Increased purity Marker Plasmid Map Antibiotic Resistance Gene Origin of Replication mRNA yield Competitors 4bb • All key competitors feed plasmid dire
Slide 13: Commercial Progress
Commercial Progress i} Abasebio
Slide 14: Commercial Highlights
Commercial Highlights Client # • Client based increased to over 90 clients + 35% • Repeat business shows client satisfaction and adoption of synthetic DNA GMP value: Commercial Repeat +400% Progress >25% • Growing pipeline of new opportunities to drive growth into 2026 • Increasingly strong engageme
Slide 15: Go-to-Market Strategy: Shift in Customer Acquisition Point
Go-to-Market Strategy: Shift in Customer Acquisition Point Historically, Customers Enter in Development Stage Client might evaluate product DNA Commercial Relationship Start ‘Off-The-Shelf’ Construct performance vs. pDNA using in-house Typically, processes Product Evaluation Low Mass Using Research
Slide 16: Commercial Drivers for Success
Commercial Drivers for Success Key Near-Term Revenue Drivers Revenue Evolution £million ✓ Significant value derives from clinical progression of current contracts As Reported Analyst Base Case ✓ Clear commercial strategy in place 45.0 m ✓ Rapid new client uptake driven by targeted business developme
Slide 17: Broad and Diversified Client Base
Broad and Diversified Client Base Growing client base across a wide range of application areas, regions and client type 9% 8% 6% 9% 13% 17% 5% 43% 6% 49% 52% 9% 20% 32% 14% 8% mRNA AAV Gene Editing Biotechnology Pharmaceutical US EU UK APAC CDMO Startup DNA Vaccine NVV Other Academic Other 17 17
Slide 18: Clear Plan to Commercialise
Clear Plan to Commercialise Innovative & Disruptive Technology Platform for Genetic Medicine & Vaccines Evolution of Product Grade Evolution of Client Base Value Count 100% 100% 80% 80% 60% GMP 60% GMP Repeat HQ HQ 40% 40% New RUO RUO 20% 20% 0% 0% 2022 2023 2024 2022 2023 2024 2022 2023 2024 Commer
Slide 19: ATMP Manufacturing Value Chain
ATMP Manufacturing Value Chain upstream downstream mRNA LNPs Enzymes, dNTPs,… Raw Materials AVV / Lenti CDMOs DNA Genome Editing DNA template 4BB core focus ATMP developers De novo synthesis DNA vaccines DNA Takes Center-stage in the ATMP Manufacturing Value Chain Upstream and Downstream Growth Oppo
Slide 20: Financial Overview
Financial Overview i} Abasebio
Slide 21: Financial Overview
Financial Overview Income Statement Cashflows [in £‘ 000] 2024 2023 Com m e nts [in £’000] 2024 2023 Comments Revenues 933 506 • Doubling of DNA Net loss for the period (12,333) (7,665) • Operating cashflows revenue Income taxes (321) (689) reflect continued Cost of goods sold (303) (166) growth of
Slide 22: Financial Overview
Financial Overview Balance Sheet - Assets Balance Sheet – Equity and Liabilities [in £’000] 2024 2023 Comments [in £’000] 2024 2023 Comments Assets • Further property Liabilities • Current liabilities Intangible assets 3,480 2,669 additions Financial liabilities (188) (392) increasing as business Tr
Slide 23: Financial Overview: 2025 Outlook
Financial Overview 2025 Outlook • Continued strong growth in revenues • Strengthening of Commercial, Manufacturing and Platforms teams • Headcount to reach about 145 • Funding of activities through cash balances following November 2024 investment 23
Slide 24: Summary & Outlook
Summary & Outlook i} Abasebio
Slide 25: 2025 Key Objectives
2025 Key Objectives 2025 Deliverables Build on Commercial Momentum • Advance marketing driven lead generation • Expand commercial footprint in USA • Capitalise on momentum in APAC • Build and Strengthen GMP order book Invest in Capacity Build-out • Expand client on-boarding capabilities (RUO) • Upgr
Slide 26: Differentiated and Valuable Product Offering - Significant Growth Opportunity Ahead
Differentiated and Valuable Product Offering - Significant Growth Opportunity Ahead Proprietary and disruptive technology in DNA synthesis offering a differentiated cost-effective-to-scale, quicker, safer and more flexible solution vs. incumbent methods of DNA manufacturing, with unparalleled access
Slide 27: Thank you for joining us
The Future is Synthetic Thank you for joining us www.4basebio.com 30 June 2025 27